Minor Splicing Inhibition Yields Drug Leads for KRAS-Driven Cancers
In vivo proof-of-concept in zebrafish, mouse and human models confirmed that minor splicing blockade triggers p53-dependent tumor cell death, paving the way for initial inhibitor candidates to enter development.
